- 询价
- gelatins
- JC162471
- 进口/国产
- 2025年07月10日
- ELISA, WB
- Rabbit
- 人/动物/植物
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 供应商：
上海机纯实业有限公司
- 库存：
大量
- 克隆性：
多克隆
- 保质期：
12个月
- 抗体英文名：
Anti-UTS2B antibody
- 宿主：
Rabbit
- 适应物种：
人/动物/植物
- 应用范围：
ELISA, WB
- 浓度：
0.2 mg/ml
- 保存条件：
-20°C
- 规格：
25 μl/100 μl/200 μl
Cat. No. JC162471
Package 25 μl/100 μl/200 μl
Storage -20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
Product overview
Description Anti-UTS2B rabbit polyclonal antibody
Applications ELISA, WB, IHC
Immunogen Synthetic peptide of human UTS2B
Reactivity Human
Content 0.2 mg/ml
Host species Rabbit
Ig class Immunogen-specific rabbit IgG
Purification Antigen affinity purification
Anti-UTS2B antibody
Target information
Symbol UTS2B
Full name urotensin 2B
Synonyms U2B; URP; UTS2D
Swissprot Q765I0
Target Background
Potent vasoconstrictor.Human Urotensin II is composed of only 11 amino acid residues, while fish and frog Urotensin II possess 12 and 13 amino acid residues, respectively (2). Human Urotensin II is found within both vascular and cardiac tissue, including coronary atheroma, and effectively constricts isolated arteries from nonhuman primates (3). Urotensin II may act as an autocrine and/or paracrine hormone rather than as a circulating hormone, by playing an important role in the development of ventricular hypertrophy induced by chronic hypoxia (4).
Anti-UTS2B antibody
Applications
Immunohistochemistry
Predicted cell location: Cytoplasm
Positive control: Human thyroid cancer
Recommended dilution: 25-100
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Genotyping Anti-Hepatitis B Virus Drug Resistance
Agents available or in development for the treatment of chronic hepatitis B virus (HBV) infection fall into two major groups: immunomodulators, such as interferon-α and therapeutic vaccines, and nucleoside/nucleotide analogs
Induction of Anti-Hepatitis B Virus Immune Responses Through DNA Immunization
Cellular and humoral immune responses to different hepatitis B virus (HBV) antigens are believed to play an essential role in the elimination of virus by the host. It is well established that the humoral immune response to HBV envelope
Designing Clinical Development Programs for Anti-Hepatitis B Virus Drugs
Hepatitis B virus (HBV) infection remains one of the leading infectious causes of chronic liver disease and death in the world (1 ,2 ). With the advent of universal HBV vaccination and with the availability of antiviral therapeutics, HBV
